**BOSTON SCIENTIFIC CORP** 

Form 8-K January 03, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

\_\_\_\_\_

FORM 8-K

**CURRENT REPORT** 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 3, 2011

## BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in charter)

DELAWARE 1-11083 04-2695240 (State or other (Commission (IRS employer jurisdiction of file number) identification no.)

incorporation)

One Boston Scientific Place, Natick, Massachusetts (Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### ITEM 8.01. OTHER EVENTS.

On January 3, 2011, the Company announced that it has completed the sale of its Neurovascular business to Stryker Corporation, following the signing of a definitive agreement announced on October 28, 2010.

In addition, the Company announced the prepayment on December 31, 2010 of all \$600 million of its 6.00 percent senior notes due June 15, 2011, using cash on hand.

A copy of the Company's press release announcing both of these matters is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No. Description

99.1 Press Release issued by Boston Scientific Corporation dated January 3, 2011.

### **SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 3, 2011 BOSTON SCIENTIFIC CORPORATION

By: /s/ Vance R. Brown Vance R. Brown

Vice President and Chief Corporate Counsel

# INDEX TO EXHIBITS

Exhibit No. Description

99.1 Press Release issued by Boston Scientific Corporation dated January 3, 2011.